Physician profile
Michael T Hernando
NPI 1902017296
$6,330.95
in general payments reported to CMS, 2019-2025
26 companies · $604 in 2025
The $604 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,526 · 2020: $50.10 · 2021: $94.16 · 2022: $404 · 2023: $374 · 2024: $2,277 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,644 · Food and Beverage: $1,612.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,643.90 |
| Food and Beverage | $1,612.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tela Bio, INC. | $2,537.63 | 2020-2025 | Ovitex 2s, Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Intuitive Surgical, INC. | $2,399.45 | 2019-2022 | |
| Davol INC. | $449.25 | 2019-2025 | Phasix Mesh |
| W. L. Gore & Associates, INC. | $216.80 | 2023-2024 | Gore Enform Preperitoneal Biomaterial, Gore Synecor Biomaterial |
| Merck Sharp & Dohme LLC | $94.02 | 2021-2025 | Keytruda, Lynparza |
| Glaxosmithkline, LLC. | $87.34 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Ethicon US, LLC | $66.38 | 2019 | |
| Amgen INC. | $53.13 | 2022-2023 | Lumakras |
| Novo Nordisk INC | $49.10 | 2019 | |
| Becton, Dickinson and Company | $42.18 | 2024 | Channel Drain |
| Axsome Therapeutics, INC. | $31.36 | 2024-2025 | Sunosi |
| Polynovo North America LLC | $30.16 | 2022 | |
| Jazz Pharmaceuticals INC. | $29.11 | 2021 | |
| Boston Scientific Corporation | $25.69 | 2022 | |
| Baxter Healthcare | $24.52 | 2025 | Hillrom - Monarch Airway Clearance System |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $22.27 | 2025 | Enhertu |
| Corcept Therapeutics | $20.69 | 2024 | Korlym |
| Lexicon Pharmaceuticals, INC. | $20.36 | 2023 | Inpefa |
| Janssen Biotech, INC. | $20.02 | 2025 | Rybrevant |
| Alexion Pharmaceuticals, INC. | $18.87 | 2025 | Ultomiris |
| Seagen INC. | $17.63 | 2019 | |
| Integra Lifesciences Corporation | $17.14 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.00 | 2019 | |
| Amarin Pharma, INC. | $14.99 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.47 | 2022 | |
| Daiichi Sankyo INC. | $13.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hernando listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.